The declining dose estimates with age describe a research endpoint under a specified opioid-containing protocol.
The dose-finding study divided ERCP patients aged fifty to eighty-nine into four age bands. Estimated remimazolam ED50 values decreased from approximately 0.122 to 0.108, 0.093 and 0.078 mg/kg across the bands. Patients first received sufentanil, and success required the specified sedation response and ability to proceed with ERCP. Older age was strongly associated with lower estimated requirement.
An ED50 is a population estimate for fifty-percent effectiveness, not an amount guaranteed to work for an individual. Sequential designs are especially sensitive to endpoint definition and provide less precise information about high-success doses. Comorbidities were not systematically collected, and few participants in the oldest group were eighty-five or older.
Before comparing an individual exposure with this paper, preserve the opioid, timing, age range and success definition. A dose-finding estimate is not a toxic concentration or an impairment threshold. Age-related sensitivity cannot establish whether a particular person was conscious, amnestic or adequately ventilating. The paper supports asking how age and the medication package affect response, while requiring individual observations for any case-specific conclusion.
Source: PMC12595939, supplied full-text paper. Findings are paraphrased; forensic implications are an interpretation.
Related: Three-Drug ERCP Sedation Compared Age Groups Rather Than Isolated Medicines.